



## Supplementary Data



**SUPPLEMENTARY FIG. S1.** Cellular counts in peripheral blood from healthy controls and HIV-1-infected patients with or without OI. The percentages of monocytes, mDCs, and pDCs are shown in the three groups of patients (upper panel) and also when HIV-1-infected patients with OI were classified according to the use of HAART (lower panel). Comparisons were made by Kruskal-Wallis ANOVA tests and Dunn's post-tests. The level of significance is  $p < 0.05$  (\*) and  $p < 0.01$  (\*\*); controls ( $n = 21$ ), HIV -OI (HIV-1-infected patients without OIs,  $n = 39$ ), HIV +OI (HIV-1-infected patients with OIs) with HAART ( $n = 4$ ) and without HAART ( $n = 6$ ). Similar results were observed with the absolute counts (data not shown).



**SUPPLEMENTARY FIG. S2.** Evaluation of TLR2 and TLR4 expression on plasmacytoid dendritic cells. **(A)** The pDCs were selected as BDCA-2<sup>+</sup> CD123<sup>high</sup> cells from the PBMC region. Then, TLR2 (blue histogram) and TLR 4 (green histogram) expression on pDCs was determined by flow cytometry, and using the isotype control IgG2a PE (gray histogram). The M1 mark shows the TLRs positive cells (percentage), and the MFI was calculated from the overall pDC population. **(B)** pDCs were purified using the Diamond Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotecs, Germany), which combines isolation of pDCs by depletion of T cells, B cells, NK cells, mDCs, monocytes, granulocytes, and erythroid cells, and their subsequent positive selection. After following the purification protocol, the cells were evaluated for TLR2 and TLR4 expression by flow cytometry. **(C)** Total RNA was obtained from purified pDCs and total PBMCs. The cDNA was synthesized and real time PCR was performed to detect TLR2 and TLR4. The following controls were used:  $\beta$ -actin (housekeeping gene), BDCA-2 (pDC-specific marker), TLR9 (highly expressed in pDCs), and TLR3 (not expressed in pDCs).